Stoke Therapeutics, Inc.
STOKBiotechnology
$26.35−0.23%As of Oct 29vs prior close
- Market cap
- $1.7B
- P/E (TTM)
- –
- From 52W high
- −31.29%
- EPS (LTM)
- -$3.34
- Revenue (LTM)
- $27.6M
- Net margin
- -753.60%
- Dividend yield
- 0.00%
Nomior Score
24
Distressed LaggardSpeculativeBottom 10% of the scored universe
Growth57
Quality30
Value37
Momentum28
Resilience29
Growth
+145.89%revenue a year over 3 fiscal years
FY22 $12.4MLTM $27.6M
Connections
Revenue to profitQ2 FY26
The operating loss was 702% of revenue, wider by 504 pts on a year.
Latest resultsthird quarter 2026
- Revenue
- $11.3 million
- Net loss
- $73.6 million
Revenue for the quarter rose slightly from the same period last year, while research and development and sales, general and administrative expenses increased sharply on zorevunersen advancement and launch readiness. The company reported a net loss for the quarter. The release gives no adjusted earnings or guidance for the period.
Who owns it
2funds